Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations examine located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://vasilievichz023xmg5.livebloggs.com/profile